Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Drugs Improve Range of Options for Osteoporosis: 3
March 7, 2011
- PIII Results for Afinitor Published in NEJM
March 7, 2011
- Korosho Approves Norspan, NorLevo after One-Month Delay
March 7, 2011
- Avastin Prolongs PFS in Ovarian Cancer
March 7, 2011
- Nesina Approved for Coadministration with SU and BG: Takeda
March 7, 2011
- JAMS Announces GLs for COI Management
March 7, 2011
- Xeloda Approved for Advanced/Recurrent Stomach Cancer: Chugai
March 7, 2011
- 8 Companies to Withdraw Generic Versions of Dasen
March 7, 2011
- GSK Starts Multinational PIII Study for DMD
February 28, 2011
- Pfizer to Stress Significance of Combining CCB, Statin in One Drug
February 28, 2011
- Increasing Number of Trials Conducted on Concurrent Use of Oral Hypoglycemic Agents
February 28, 2011
- Mylan Aims to Become Top-3 Generic Company in Japan in 5 Years
February 28, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Lixisenatide Not Inferior to Exenatide in PIII: sanofi-aventis
February 28, 2011
- ARB + CCB Combination Drugs Ranked in Top Positions in HP, GP Markets: RepTrack Survey
February 28, 2011
- WT1 mRNA Assay Kit Otsuka Approved for MDS
February 28, 2011
- New Drugs Improve Range of Options for Osteoporosis: 2
February 28, 2011
- Otsuka HD to Establish Otsuka Medical Devices
February 28, 2011
- Cooperation beyond National Boundaries Necessary in Asia: JPMA President Hasegawa
February 28, 2011
- Takara Bio to Create Research Reagent Joint Venture in India
February 28, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…